Tailored cancer cocktail tested for tough childhood tumor
NCT ID NCT02780128
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested a personalized approach for children with relapsed or hard-to-treat neuroblastoma. Doctors used a tumor biopsy to find genetic changes and then assigned a combination of targeted drugs (ceritinib and ribociclib) to match those changes. The study was terminated early, but it aimed to see if this strategy could shrink tumors and be safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ceritinib and ribociclib
What this could lead to
If successful, this approach could point toward more effective, personalized treatments for children with relapsed neuroblastoma.
What could go wrong
This was a very early (phase 1) trial that was terminated, so results are limited. The combination drugs may cause significant side effects and may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States